Industry & Policy News

[University of Strathclyde] Researchers at the University of Strathclyde have been awarded £2.6 million to develop a preclinical lead drug candidate targeted at advanced prostate and colorectal cancers.

[Monte Rosa Therapeutics, Inc.] Monte Rosa Therapeutics, Inc. announced a novel development candidate, MRT-8102. MRT-8102 is expected to be developed for the treatment of inflammatory diseases driven by interleukin-1β and the NLRP3 inflammasome, which are critical elements of the inflammatory process.

[Sifted] Cellcolabs has raised $8.7m from angel investors to expand production facilities and grow employee headcount. The Sweden-based company manufactures specialised stem cells that can be used to develop cell therapy treatments for diseases associated with inflammation.

[OncLive] The FDA has approved inotuzumab ozogamicin for the treatment of pediatric patients aged one year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.

[UCLA Health] A team of investigators from the UCLA Health Jonsson Comprehensive Cancer and the University of Arkansas for Medical Sciences Winthrop P. Rockefeller Cancer Institute was awarded a $3.2 million grant from the National Institutes of Health to identify new ways to prevent and overcome treatment resistance to targeted therapy in patients with all sub-types of cutaneous melanoma.

[Mirage] A research team from Kumamoto University employed advanced techniques, including next-generation sequencing to comprehensively analyze vascular endothelial cells stimulated by the potent VEGF and were subjected to a comprehensive analysis.